BRISBANE and MINNEAPOLIS, Australia – (BUSINESS WIRE) – Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR) is a structural heart company developing the world’s only ball for therapeutic use Balloon-Expandable Monolithic Transcatheter Aortic Valve (TAVR) for Aortic Stenosis today announced that Anteris CEO Wayne Paterson will present at Cantor in New York, NY on Tuesday, September 26, 2023 at 2:45 pm ET Fitzgerald Annual Global Healthcare Conference.
Mr. Paterson will present the latest clinical data on DurAVR™, the company’s leading technology and first-in-class TAVR for the treatment of aortic stenosis. This will be followed by a fireside chat with Cantor’s medical technology analyst Ross Osborne. Investor one-on-one meetings are also available at the conference and institutional investors interested in arranging a meeting should contact their Cantor salesperson or Cantor’s Corporate Access team at Corporateaccess@cantor.com
DurAVR™ THV continues to be studied in clinical trials in patients with severe aortic stenosis in two early feasibility studies (EFS) conducted in the United States (ClinicalTrials.gov NCT05712161) and Europe (ClinicalTrials.gov NCT05182307). One-year data for DurAVR™ European EFS presented at TVT Structural Heart Conference on June 9th 2023 and can be viewed on the Investor Portal of the Company’s website. Thirty (30) days of data results from DurAVR™’s ongoing U.S. EFS are expected to be released in the fourth quarter of 2023.
About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd (ASX: AVR) is a cardiac structures company focused on the design, development and commercialization of innovative medical devices. Founded in Australia with a significant presence in the Minneapolis Medical Technology Center in the United States, Anteris is science-driven and has an experienced team of multidisciplinary professionals delivering transformative solutions for patients with structural heart disease.
The company’s lead product, DurAVR™, is a transcatheter heart valve (THV) used to treat aortic stenosis. Designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons, the DurAVR™ THV is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. The bionic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.
The ComASUR™ Delivery System is designed to provide controlled deployment and accurate placement of the DurAVR™ THV via balloon-expandable delivery, resulting in precise alignment with the heart’s native commissures to achieve desired valve positioning.
Anteris Technologies is committed to revolutionizing the structural heart market by delivering clinically superior solutions that address significant unmet clinical needs.
Authorization and additional information:
This announcement has been approved by the company’s board of directors.
Websitewww.anteristech.com
Twitter @AnterisTech
Facebook www.facebook.com/AnterisTech
LinkedIn https://www.linkedin.com/company/anteristech
Contact information
Investor Relations (US)
Dr Malini Chatterjee
managing Director
Blueprint Life Sciences Group
+1 917 330 4269
Source link
Content provided by Business Wire. Toutiao is not responsible for the content provided or any links related to that content. Toutiao is not responsible for the accuracy, topicality or quality of the content.
